The presence of the compensation mechanism among RUNX family members (RUNX1, RUNX2, and RUNX3) [10, 11] prompted us to imagine that targeting whole RUNX family could be an effective strategy to suppress the malignant phenotypes of leukemia cells. Here, RUNX1 is linked to leukemia.